Claas Wesseler

694 total citations
23 papers, 176 citations indexed

About

Claas Wesseler is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Neurology. According to data from OpenAlex, Claas Wesseler has authored 23 papers receiving a total of 176 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 5 papers in Neurology. Recurrent topics in Claas Wesseler's work include Lung Cancer Treatments and Mutations (13 papers), Cancer Genomics and Diagnostics (5 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Claas Wesseler is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Cancer Genomics and Diagnostics (5 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Claas Wesseler collaborates with scholars based in Germany, Hungary and United States. Claas Wesseler's co-authors include Petra Hoffknecht, Gunther H. Wiest, Wolfgang M. Brueckl, Martin Reck, Eckart Laack, Bernhard Ulm, Achim Rittmeyer, Joachim H. Ficker, Jens Kollmeier and Petros Christopoulos and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Claas Wesseler

23 papers receiving 175 citations

Peers

Countries citing papers authored by Claas Wesseler

Since Specialization

Citations

This map shows the geographic impact of Claas Wesseler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claas Wesseler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claas Wesseler more than expected).

Fields of papers citing papers by Claas Wesseler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claas Wesseler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claas Wesseler. The network helps show where Claas Wesseler may publish in the future.

Co-authorship network of co-authors of Claas Wesseler

This figure shows the co-authorship network connecting the top 25 collaborators of Claas Wesseler. A scholar is included among the top collaborators of Claas Wesseler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claas Wesseler. Claas Wesseler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions 2024 ·Future Oncology ·Dong‐Wan Kim, Alison M. Schram, Antoine Hollebecque, Kazumi Nishino, Teresa Macarulla, Sun Young Rha, M. Duruisseaux, Stephen V. Liu, Mohammed Najeeb Al Hallak, Kumiko Umemoto, Claas Wesseler, James M. Cleary, Christoph Springfeld, Cindy Neuzillet, Andrew K. Joe, (unknown), (unknown), Kōichi Goto	27
2	Kriterien für die Behandlung von thoraxonkologischen Erkrankungen als stationäre Leistung bei Erwachsenen * 2024 ·Pneumologie ·Nikolaj Frost, Claas Wesseler, Bernhard Wörmann, Wilfried Eberhardt	1
3	1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy 2023 ·Annals of Oncology ·(unknown), Jörg Möller, Sebastian Michels, Christian Grohé, Marcel Wiesweg, Christoph D. Schubart, (unknown), Frank Griesinger, Diego Kauffmann‐Guerrero, (unknown), Tobias R. Overbeck, (unknown), Gernot Rohde, Claas Wesseler, Ioannis Vathiotis, Rajwanth Veluswamy, (unknown), Sacha I. Rothschild, Petros Christopoulos, Martin Wermke	1
4	High In-Hospital Mortality in SARS-CoV-2-Infected Patients with Active Cancer Disease during Omicron Phase of the Pandemic: Insights from the CORONA Germany Study 2023 ·Oncology Research and Treatment ·(unknown), Nele Geßler, Peter Wohlmuth, Jürgen Behr, Johannes Feldhege, Christian Johannes Gloeckner, Melanie Gunawardene, Klaus Herrlinger, Thomas Hoelting, Ulrich‐Frank Pape, Niels Reinmuth, Axel Stang, (unknown), Dirk Arnold, Claas Wesseler	3
5	Nivolumab with chemotherapy in pleural mesothelioma after surgery: The NICITA trial. 2023 ·Journal of Clinical Oncology ·Rajiv Shah, Laura V. Klotz, Daniel C. Christoph, Karsten Schulmann, Hans‐Georg Kopp, Niels Reinmuth, Michael Ried, Maike de Wit, (unknown), Claas Wesseler, Martin Reck, (unknown), Cornelius F. Waller, Petra Hoffknecht, (unknown), Marc A. Schneider, Rouven Behnisch, Petros Christopoulos, Martin Eichhorn, Michael Thomas	1
6	NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy 2022 ·Lung Cancer ·Arne Trummer, (unknown), Nicolas Dickgreber, (unknown), Heiko Golpon, Petra Hoffknecht, Tobias R. Overbeck, Claas Wesseler, Martin Reck	6
7	NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy. 2022 ·Journal of Clinical Oncology ·Arne Trummer, (unknown), Nicolas Dickgreber, (unknown), Heiko Golpon, Petra Hoffknecht, Tobias R. Overbeck, Claas Wesseler, Martin Reck	2
8	Clinical outcome, risk assessment, and seasonal variation in hospitalized COVID-19 patients—Results from the CORONA Germany study 2021 ·PLoS ONE ·Nele Geßler, Melanie Gunawardene, Peter Wohlmuth, Dirk Arnold, Jürgen Behr, Christian Johannes Gloeckner, Klaus Herrlinger, Thomas Hoelting, Ulrich‐Frank Pape, (unknown), Axel Stang, Claas Wesseler, Stephan Willems, (unknown), Christoph U. Herborn	11
9	Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors 2021 ·Pathology - Research and Practice ·(unknown), Markus Falk, Lukas C. Heukamp, Stefanie Schatz, Markus Tiemann, Claas Wesseler, Linda Diehl, Ed Schuuring, Harry J.M. Groen, Frank Griesinger	2
10	Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV 2021 ·Translational Lung Cancer Research ·Wolfgang M. Brueckl, Martin Reck, Achim Rittmeyer, Jens Kollmeier, Claas Wesseler, Gunther H. Wiest, Petros Christopoulos, Albrecht Stenzinger, Amanda Tufman, Petra Hoffknecht, Bernhard Ulm, (unknown), Joachim H. Ficker, Eckart Laack	27
11	1912TiP NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery 2020 ·Annals of Oncology ·Rajiv Shah, Laura V. Klotz, Manuel Feißt, Martina Schneider, Mark Kriegsmann, Michael Ried, Claas Wesseler, Daniel C. Christoph, Maike de Wit, (unknown), H-G. Kopp, Thomas Wehler, M. Reck, (unknown), Cornelius F. Waller, Niels Reinmuth, Helge Bischoff, H. Winter, Martin Eichhorn, Monica A. Thomas	1
12	Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV 2020 ·Clinical Medicine Insights Oncology ·Wolfgang M. Brueckl, Martin Reck, Achim Rittmeyer, Jens Kollmeier, Claas Wesseler, Gunther H. Wiest, Petros Christopoulos, Amanda Tufman, Petra Hoffknecht, Bernhard Ulm, (unknown), Joachim H. Ficker, Eckart Laack	24
13	Treatment patterns of EGFR mt+ NSCLC IV pts: Real-world data of the NOWEL network 2019 ·Annals of Oncology ·(unknown), Markus Falk, Stefanie Schatz, Markus Tiemann, Claas Wesseler, (unknown), (unknown), D. Ukena, Frank Griesinger	1
14	Risk of not receiving 2nd line therapy is high in EGFR mt+ patients: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients 2019 ·Pneumologie ·(unknown), Markus Falk, Stefanie Schatz, Markus Tiemann, (unknown), D. Ukena, Claas Wesseler, (unknown), Lukas C. Heukamp, Frank Griesinger	1
15	Risk of not receiving second-line therapy is high in EGFR mt+ patients: Real-world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients 2019 ·Annals of Oncology ·(unknown), (unknown), Markus Falk, Stefanie Schatz, Markus Tiemann, Claas Wesseler, Gerald Wiest, (unknown), D. Ukena, Lukas C. Heukamp, Frank Griesinger	1
16	P1.01-82 Risk of Not Receiving 2nd Line Therapy is High in EGFR mt+ pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR mt+ pts 2018 ·Journal of Thoracic Oncology ·(unknown), Martin Falk, Stefanie Schatz, Markus Tiemann, (unknown), D. Ukena, Claas Wesseler, Gerald Wiest, Lukas C. Heukamp, Frank Griesinger	7
17	Risk of not receiving 2^nd line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts. 2018 ·Journal of Clinical Oncology ·(unknown), Markus Falk, Markus Tiemann, Claas Wesseler, Gunther H. Wiest, (unknown), D. Ukena, Lukas C. Heukamp, Frank Griesinger	8
18	A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER. 2018 ·Journal of Clinical Oncology ·Jonathan W. Goldman, Julien Mazières, Fabrice Barlési, Marianna Koczywas, Konstantin H. Dragnev, Tuncay Göksel, Alexis B. Cortot, Nicolas Girard, Claas Wesseler, Helge Bischoff, Ernest Nadal, Keunchil Park, Shun Lü, Álvaro Taus, Manuel Cobo, Karla Hurt, Alan Y. Chiang, Anwar Hossain, William J. John, Luis Paz‐Ares	22
19	Impact on OS and PFS of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ pts: Results of the NOWEL network 2017 ·Annals of Oncology ·(unknown), (unknown), (unknown), Markus Falk, Cora Hallas, Markus Tiemann, (unknown), Lukas C. Heukamp, Claas Wesseler, Gerald Wiest, D. Ukena, (unknown), Frank Griesinger	5
20	Impact on OS of 2^nd and 3^rd generation TKI in EGFR mt+ and ALK+ patients: Results of the NOWEL network. 2017 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), Cora Hallas, Markus Tiemann, (unknown), Lukas C. Heukamp, Markus Falk, Gunther H. Wiest, Claas Wesseler, D. Ukena, (unknown), Frank Griesinger	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact